![](https://weeklysauce.com/wp-content/uploads/2023/08/image-2663848327.jpg)
All infants should receive the new long-acting preventive monoclonal antibody for respiratory syncytial virus (RSV), the nation’s leading pediatrics group said. The American Academy of Pediatrics (AAP) urged that access to the new medication, called nirsevimab, be equitable. RSV is common, contagious and sometimes deadly, the AAP said. The antibody boosts the immune system. The… read on > read on >